Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M605Revenue (TTM) $M7.9Net Margin (%)-851.0Altman Z-Score3.9
Enterprise Value $M399EPS (TTM) $-2.0Operating Margin %-881.8Piotroski F-Score4
P/E(ttm)--Beneish M-Score1.3Pre-tax Margin (%)-854.7Higher ROA y-yY
Price/Book4.010-y EBITDA Growth Rate %--Quick Ratio4.9Cash flow > EarningsY
Price/Sales70.05-y EBITDA Growth Rate %--Current Ratio4.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-52.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-70.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M39.5ROIC % (ttm)273Gross Margin Increase y-yN

Gurus Latest Trades with CARA

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

CARA is held by these investors:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History

CARA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CHALMERS DEREK TPresident & CEO 2019-01-04Sell20,000$13.6112.71view
Menzaghi Frederique Ph.D.Sr VP-Research & Development 2018-12-28Sell4,300$12.5322.43view
Terrillion ScottSec'y; Chief Compliance & G.C. 2018-12-28Sell3,100$12.5122.62view
CHALMERS DEREK TPresident & CEO 2018-12-28Sell15,825$12.5322.43view
Mohindru ManiCFO & Chief Strategy Officer 2018-12-28Sell4,500$12.5522.23view
Menzaghi Frederique Ph.D.Sr VP-Research & Development 2018-12-03Sell3,000$18.36-16.45view
CHALMERS DEREK TPresident & CEO 2018-12-03Sell20,000$18.17-15.58view
Mohindru ManiCFO & Chief Strategy Officer 2018-11-15Sell16,042$18.5-17.08view
CHALMERS DEREK TPresident & CEO 2018-11-01Sell20,000$18.78-18.32view
Menzaghi Frederique Ph.D.Sr VP-Research & Development 2018-11-01Sell3,000$18.77-18.27view

Press Releases about CARA :

Quarterly/Annual Reports about CARA:

    News about CARA:

    Articles On GuruFocus.com
    Cara Therapeutics Completes Enrollment of KALM-1 Pivotal Phase 3 Trial Of KORSUVA™ (CR845/ difelik Jan 07 2019 
    Cara Therapeutics Announces No Modifications in Trial Size After Completion of Interim Statistical A Jan 02 2019 
    Cara Therapeutics: Stock to Own in 2019 - Value Idea Contest Dec 31 2018 
    Cara Therapeutics to Present at November Investor Conferences Nov 08 2018 
    Cara Therapeutics to Announce Third Quarter 2018 Financial Results on November 6, 2018 Oct 30 2018 
    Cara Therapeutics Appoints Joana Goncalves, M.D., as Chief Medical Officer Oct 23 2018 
    Cara Therapeutics to Present at the 2018 Cantor Global Healthcare Conference Sep 26 2018 
    Cara Therapeutics to Present at the 27th European Academy of Dermatology & Venereology Congress Sep 05 2018 
    Cara Therapeutics Doses First Patient in Second Pivotal Phase 3 Efficacy Trial of KORSUVA™ (CR845/ Aug 07 2018 
    Cara Therapeutics Appoints Christopher A. Posner to Board of Directors Aug 06 2018 
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat